HERIZON-GEA-01 Efficacy Results and Interpretation of Duration of Response
HORIZON-GA01 shows zenidatamab regimens significantly improve survival in HER2-positive gastric cancer, while PD-L1 testing differences raise key questions for treatment choice.
source
Reporting by onclive. The original article may no longer be reachable at its published URL.
read at onclive ↗
comments(0)
5-min edit window · permanent after that